Multiple System Atrophy Clinical Trial
Official title:
Evaluation of the Subjective and Objective Painful Threshold in Multiple System Atrophy Pain and Multiple System Atrophy
Multiple system atrophy (MSA) is a sporadic neurodegenerative disorder. MSA is dominated by
autonomic/urogenital failure which may be associated with either Parkinsonism (MSA-P
subtype) or with cerebellar ataxia (MSA-C subtype). The prognostic of this disease is bad
because it ended with the patient's death few years later. No neuroprotective treatment has
shown a real efficacy. 50% of patients suffering of MSA frequently experienced painful
sensation. The origin of this pain is unknown. In Parkinson disease (PD) ; arguments suggest
the implication of dopamine neuromediator pathway in integration and modulation of pain.
Several studies suggest the existence of various influences with dopamine implication in the
appearance of painful sensation and that would be inhibitory. That's why observed painful
symptoms in MSA and PD could be due to a decrease of pain appearance threshold, secondary to
a lost of control of sensitizes centres, to Parkinson control.
It is interesting to determine if MSA as PD is responsible for a decrease of pain threshold
and to characterise the levodopa effect on the patient's pain threshold. Better
physiopathology knowledge of pain in MSA is necessary to improve the therapeutic care.
Because the efficacy of others treatments is low, it's important to improve the research for
a better comfort of patients with a better understanding, analysing and treating of the
pain.
n/a
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03593512 -
Deep Brain Stimulation for Autonomic and Gait Symptoms in Multiple System Atrophy
|
N/A | |
| Recruiting |
NCT03648905 -
Clinical Laboratory Evaluation of Chronic Autonomic Failure
|
||
| Active, not recruiting |
NCT05699460 -
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
|
||
| Recruiting |
NCT02897063 -
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
|
Phase 1 | |
| Not yet recruiting |
NCT00758849 -
Fipamezole in Neurogenic Orthostatic Hypotension
|
Phase 2 | |
| Completed |
NCT01155492 -
Increased Gut Permeability to Lipopolysaccharides (LPS) in Parkinson's Disease
|
N/A | |
| Recruiting |
NCT04431713 -
Exenatide Once-weekly as a Treatment for Multiple System Atrophy
|
Phase 2 | |
| Completed |
NCT04184063 -
Study of NBMI Treatment in Patients With Atypical Parkinsons (PSP or MSA)
|
Phase 2 | |
| Recruiting |
NCT05121012 -
Synaptic Loss in Multiple System Atrophy
|
||
| Terminated |
NCT03589976 -
A Futility Trial of Sirolimus in Multiple System Atrophy
|
Phase 2 | |
| Recruiting |
NCT04706234 -
Systematic Assessment of Laryngopharyngeal Function in Patients With MSA, PD, and 4repeat Tauopathies
|
||
| Completed |
NCT00368199 -
Transcranial Duplex Scanning and Single Photon Emission Computer Tomography (SPECT) in Parkinsonian Syndromes
|
N/A | |
| Recruiting |
NCT04472130 -
Neurodegenerative Diseases Registry
|
||
| Recruiting |
NCT04876326 -
Potential Use of Autologous and Allogeneic Mesenchymal Stem Cells in Patients With Multiple System Atrophy
|
N/A | |
| Recruiting |
NCT04680065 -
GDNF Gene Therapy for Multiple System Atrophy
|
Phase 1 | |
| Completed |
NCT03753763 -
Safinamide for Multiple System Atrophy (MSA)
|
Phase 2 | |
| Recruiting |
NCT04250493 -
Insulin Resistance in Multiple System Atrophy
|
N/A | |
| Recruiting |
NCT06072105 -
Medical Decision Making in Multiple System Atrophy
|
N/A | |
| Terminated |
NCT02149901 -
Water and Sudafed in Autonomic Failure
|
Early Phase 1 | |
| Terminated |
NCT00997672 -
Lithium in Multiple System Atrophy
|
Phase 2 |